John M Timmerman

Title(s)Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Antibody-CpG conjugates for the treatment of B cell lymphoma
    NIH R01CA149254Apr 1, 2010 - Feb 29, 2016
    Role: Principal Investigator
    Anti-CTLA-4 Monoclonal Antibody Therapy for Lymphoma
    NIH R21CA108182Sep 18, 2004 - Aug 31, 2007
    Role: Principal Investigator
    Academic Training in Hematology
    NIH T32HL066992Jul 1, 2001 - Jul 31, 2018
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Transplant Cell Ther. 2024 Aug 24. Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Kersten MJ, Zheng Y, Zhang T, Nater J, Shen R, Miao H, Kim JJ, Miklos DB. PMID: 39187161.
      View in: PubMed   Mentions: 1     Fields:    
    2. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transplant. 2024 Mar; 59(3):366-372. Oluwole OO, Forcade E, Muñoz J, de Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney P, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Zheng Y, Vardhanabhuti S, Nater J, Shen RR, Miao H, Kim JJ, van Meerten T. PMID: 38177222; PMCID: PMC10920180.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    3. Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11. Clin Cancer Res. 2023 Oct 13; 29(20):4118-4127. Jain MD, Miklos DB, Jacobson CA, Timmerman JM, Sun J, Nater J, Fang X, Patel A, Davis M, Heeke D, Trinh T, Mattie M, Neumann F, Kim JJ, To C, Filosto S, Reshef R. PMID: 37527011; PMCID: PMC10570684.
      View in: PubMed   Mentions: 2     Fields:    
    4. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023 05 11; 141(19):2307-2315. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. PMID: 36821768; PMCID: PMC10646788.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    5. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discov. 2023 03 01; 13(3):580-597. Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY. PMID: 36416874; PMCID: PMC9992104.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    6. Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy. Cancer Immunol Res. 2022 12 02; 10(12):1433-1440. Tang JP, Peters CW, Quiros C, Wang X, Klomhaus AM, Yamada RE, Timmerman JM, Moore TB, Nowicki TS. PMID: 36259217; PMCID: PMC9722515.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    7. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023 01 20; 41(3):555-567. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM. PMID: 35658525; PMCID: PMC9870225.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    8. 89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model. Mol Cancer Ther. 2022 04 01; 21(4):607-615. Zettlitz KA, Salazar FB, Yamada RE, Trinh KR, Vasuthasawat A, Timmerman JM, Morrison SL, Wu AM. PMID: 35086952; PMCID: PMC8983440.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    9. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021 08; 194(4):690-700. Oluwole OO, Bouabdallah K, Muñoz J, De Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney PA, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Kim JJ, Bashir Z, McLeroy J, Zheng Y, Rossi JM, Johnson L, Goyal L, van Meerten T. PMID: 34296427; PMCID: PMC8457222.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCTClinical Trials
    10. Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clin Lymphoma Myeloma Leuk. 2021 12; 21(12):861-872. Ghafouri S, Fenerty K, Schiller G, de Vos S, Eradat H, Timmerman J, Larson S, Mead M. PMID: 34389271.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    11. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021 02 04; 137(5):637-645. Armand P, Janssens A, Gritti G, Radford J, Timmerman J, Pinto A, Mercadal Vilchez S, Johnson P, Cunningham D, Leonard JP, Rodig SJ, Martín-Regueira P, Sumbul A, Samakoglu S, Tang H, Ansell SM. PMID: 32870269; PMCID: PMC7869188.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    12. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). J Transl Med. 2021 01 06; 19(1):13. Ascierto PA, Butterfield LH, Campbell K, Daniele B, Dougan M, Emens LA, Formenti S, Janku F, Khleif SN, Kirchhoff T, Morabito A, Najjar Y, Nathan P, Odunsi K, Patnaik A, Paulos CM, Reinfeld BI, Skinner HD, Timmerman J, Puzanov I. PMID: 33407605; PMCID: PMC7789268.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies? Bone Marrow Transplant. 2021 04; 56(4):974-977. Ghafouri S, Timmerman J, Larson S, Mead MD. PMID: 33168933; PMCID: PMC8035067.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    14. Nivolumab Treatment of Burkitt Lymphoma: A Case Report. Ann Intern Med. 2021 04; 174(4):567-568. Colton BS, Hornstein N, Timmerman J, Larson S, Glaspy J. PMID: 33105097.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019. J Immunother Cancer. 2020 08; 8(2). Ascierto PA, Bifulco C, Galon J, Garbe C, Khleif SN, McQuade J, Odunsi K, Okada H, Paulos CM, Quezada SA, Tawbi HA, Timmerman J, Trinchieri G, Butterfield LH, Puzanov I. PMID: 32843491; PMCID: PMC7449295.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia. 2021 03; 35(3):777-786. Armand P, Lesokhin A, Borrello I, Timmerman J, Gutierrez M, Zhu L, Popa McKiver M, Ansell SM. PMID: 32601377; PMCID: PMC7932914.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    17. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020 04 02; 382(14):1331-1342. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. PMID: 32242358; PMCID: PMC7731441.
      View in: PubMed   Mentions: 677     Fields:    Translation:HumansCellsCTClinical Trials
    18. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 05; 95(5):510-520. Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R. PMID: 32052473; PMCID: PMC7383599.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    19. Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):468-479. Young PA, Gaut D, Kimaiyo DK, Grotts J, Romero T, Chute J, Schiller G, de Vos S, Eradat HA, Timmerman J. PMID: 32229199; PMCID: PMC7138188.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    20. An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma. Cancer Res. 2019 05 15; 79(10):2748-2760. Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, Sasine JP, Timmerman JM, Larson SM, Kim Y, MacLeod AR, Morrison SL, Herschman HR. PMID: 30885978; PMCID: PMC6522331.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    21. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. J Clin Oncol. 2019 02 20; 37(6):481-489. Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A. PMID: 30620669; PMCID: PMC6528729.
      View in: PubMed   Mentions: 178     Fields:    Translation:HumansCellsCTClinical Trials
    22. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 01; 20(1):31-42. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. PMID: 30518502; PMCID: PMC6733402.
      View in: PubMed   Mentions: 970     Fields:    Translation:HumansCTClinical Trials
    23. 18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice. Eur J Nucl Med Mol Imaging. 2019 02; 46(2):489-500. Zettlitz KA, Tavaré R, Tsai WK, Yamada RE, Ha NS, Collins J, van Dam RM, Timmerman JM, Wu AM. PMID: 30456475; PMCID: PMC6580847.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    24. The run-down immunologic neighborhood in Hodgkin lymphoma. Blood. 2018 08 23; 132(8):770-771. Timmerman J. PMID: 30139828.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    25. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha. J Interferon Cytokine Res. 2018 06; 38(6):239-254. Young PA, Yamada RE, Trinh KR, Vasuthasawat A, De Oliveira S, Yamada DH, Morrison SL, Timmerman JM. PMID: 29920129; PMCID: PMC6007814.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    26. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018 05 10; 36(14):1428-1439. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. PMID: 29584546; PMCID: PMC6075855.
      View in: PubMed   Mentions: 293     Fields:    Translation:HumansCTClinical Trials
    27. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol. 2018 04 01; 36(10):942-950. Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA. PMID: 29394125; PMCID: PMC5877802.
      View in: PubMed   Mentions: 180     Fields:    Translation:HumansCellsCTClinical Trials
    28. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 12 28; 377(26):2531-2544. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. PMID: 29226797; PMCID: PMC5882485.
      View in: PubMed   Mentions: 2337     Fields:    Translation:HumansCellsCTClinical Trials
    29. ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization In Vivo. Clin Cancer Res. 2017 Dec 01; 23(23):7242-7252. Zettlitz KA, Tavaré R, Knowles SM, Steward KK, Timmerman JM, Wu AM. PMID: 28928164; PMCID: PMC5880625.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    30. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity. Blood. 2017 04 20; 129(16):2246-2256. Bhatt S, Parvin S, Zhang Y, Cho HM, Kunkalla K, Vega F, Timmerman JM, Shin SU, Rosenblatt JD, Lossos IS. PMID: 28137826.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    31. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. PMID: 28018601; PMCID: PMC5168808.
      View in: PubMed   Mentions: 14     Fields:    
    32. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1283-94. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A. PMID: 27451390; PMCID: PMC5541855.
      View in: PubMed   Mentions: 410     Fields:    Translation:HumansCTClinical Trials
    33. Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma. MAbs. 2016 10; 8(7):1386-1397. Vasuthasawat A, Yoo EM, Trinh KR, Lichtenstein A, Timmerman JM, Morrison SL. PMID: 27362935; PMCID: PMC5058616.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    34. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016 08 10; 34(23):2698-704. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J. PMID: 27269947; PMCID: PMC5019749.
      View in: PubMed   Mentions: 513     Fields:    Translation:HumansCellsCTClinical Trials
    35. Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection. Immunity. 2015 Feb 17; 42(2):379-390. Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, Nimmerjahn F, Brooks DG. PMID: 25680277; PMCID: PMC4334737.
      View in: PubMed   Mentions: 33     Fields:    Translation:AnimalsCells
    36. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22; 372(4):311-9. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PMID: 25482239; PMCID: PMC4348009.
      View in: PubMed   Mentions: 1702     Fields:    Translation:HumansCellsCTClinical Trials
    37. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin Oncol. 2014 Oct; 41(5):623-36. Young PA, Morrison SL, Timmerman JM. PMID: 25440607; PMCID: PMC4354941.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimals
    38. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol. 2014 Jun 12; 7:44. de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, Whiting NC, Drachman JG, Advani R. PMID: 24919462; PMCID: PMC4065310.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    39. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol. 2014 Jun 10; 32(17):1797-803. Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW. PMID: 24799467; PMCID: PMC4039868.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCellsCTClinical Trials
    40. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013 Nov 20; 31(33):4199-206. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. PMID: 24127452; PMCID: PMC4878008.
      View in: PubMed   Mentions: 205     Fields:    Translation:HumansCTClinical Trials
    41. Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas. J Immunother. 2013 Jun; 36(5):305-18. Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL. PMID: 23719241; PMCID: PMC3740795.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    42. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013 Feb 21; 121(8):1367-76. Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R. PMID: 23297127; PMCID: PMC3578953.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCells
    43. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma. J Immunother. 2012 Sep; 35(7):534-43. Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van Rooijen N, Timmerman JM. PMID: 22892450.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    44. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res. 2012 Oct 15; 18(20):5752-60. Timmerman JM, Byrd JC, Andorsky DJ, Yamada RE, Kramer J, Muthusamy N, Hunder N, Pagel JM. PMID: 22893631; PMCID: PMC5027960.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    45. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012 Jun 15; 18(12):3478-86. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. PMID: 22504044; PMCID: PMC3821872.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    46. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011 Jul 01; 17(13):4232-44. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. PMID: 21540239.
      View in: PubMed   Mentions: 157     Fields:    Translation:HumansCells
    47. Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma. Am J Hematol. 2011 Jun; 86(6):515-8. Ai WZ, Kohrt HE, Timmerman J, Hwang J, Hsu FJ, Czerwinski DD, Taidi B, Levy R. PMID: 21538469.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    48. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood. 2010 Apr 08; 115(14):2864-71. Xuan C, Steward KK, Timmerman JM, Morrison SL. PMID: 20139095; PMCID: PMC2854431.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    49. ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel. 2010 Apr; 23(4):243-9. Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, Raubitschek AA, Timmerman JM, Wu AM. PMID: 20053640; PMCID: PMC2841542.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    50. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009 Oct 15; 15(20):6446-53. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman JM. PMID: 19808874; PMCID: PMC2763019.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCTClinical Trials
    51. Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood. 2009 Nov 12; 114(20):4477-85. Varghese B, Widman A, Do J, Taidi B, Czerwinski DK, Timmerman J, Levy S, Levy R. PMID: 19762487; PMCID: PMC2777127.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    52. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009 Sep; 50(9):1500-8. Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, Raubitschek AA, Timmerman JM, Wu AM. PMID: 19690034; PMCID: PMC2852538.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimals
    53. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother. 2009 Jul-Aug; 32(6):622-31. Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM. PMID: 19483647.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    54. Carrier protein conjugate vaccines: the "missing link" to improved antibody and CTL responses? Hum Vaccin. 2009 Mar; 5(3):181-3. Timmerman JM. PMID: 19246995.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    55. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2009 Jan; 50(1):37-46. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R. PMID: 19125383; PMCID: PMC2914563.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    56. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol Immunol. 2009 Jan; 46(3):448-56. Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM. PMID: 19046770; PMCID: PMC2768258.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    57. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells. Vaccine. 2009 Jan 07; 27(2):250-9. Betting DJ, Mu XY, Kafi K, McDonnel D, Rosas F, Gold DP, Timmerman JM. PMID: 19000731; PMCID: PMC2683685.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    58. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol. 2008 Sep 15; 181(6):4131-40. Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM. PMID: 18768870.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    59. Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther. 2008 Sep; 8(9):1295-307. Andorsky DJ, Timmerman JM. PMID: 18694350.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    60. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood. 2008 Feb 01; 111(3):1504-11. Franki SN, Steward KK, Betting DJ, Kafi K, Yamada RE, Timmerman JM. PMID: 17993615; PMCID: PMC2214758.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCellsPHPublic Health
    61. Vaccine therapies for non-Hodgkin's lymphomas. Cancer Treat Res. 2006; 131:283-315. Montross S, Timmerman JM. PMID: 16704173.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    62. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol. 2005 Sep; 17(5):432-40. Hurvitz SA, Timmerman JM. PMID: 16093791.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    63. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther. 2005 Jun; 5(6):841-52. Hurvitz SA, Timmerman JM. PMID: 15952914.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    64. Cancer vaccines: pessimism in check. Nat Med. 2004 Dec; 10(12):1279; author reply 1279-80. Timmerman JM, Levy R. PMID: 15682512.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    65. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004 Dec 01; 22(23):4717-24. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. PMID: 15483014.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCellsPHPublic Health
    66. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma. Adv Pharmacol. 2004; 51:271-93. Timmerman JM. PMID: 15464914.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    67. Extending the utility of gene profiling data by bridging microarray platforms. Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10585-7. Ferl GZ, Timmerman JM, Witte ON. PMID: 12963810; PMCID: PMC196845.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    68. Immunotherapy for lymphomas. Int J Hematol. 2003 Jun; 77(5):444-55. Timmerman JM. PMID: 12841382.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    69. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst. 2003 Apr 02; 95(7):548-55. Briones J, Timmerman JM, Panicalli DL, Levy R. PMID: 12671023.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    70. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 2003 Feb; 24(2):58-61. Ribas A, Timmerman JM, Butterfield LH, Economou JS. PMID: 12547500.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    71. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002 Oct 15; 62(20):5845-52. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. PMID: 12384547.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCellsCTClinical Trials
    72. Vaccine therapies for non-Hodgkin's lymphoma. Curr Treat Options Oncol. 2002 Aug; 3(4):307-15. Timmerman JM. PMID: 12074767.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    73. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res. 2002 Jun 01; 62(11):3195-9. Briones J, Timmerman J, Levy R. PMID: 12036933.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    74. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002 Mar 01; 99(5):1517-26. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R. PMID: 11861263.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCellsCTClinical Trials
    75. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol. 2002 Feb; 30(2):135-41. Briones J, Timmerman JM, Hilbert DM, Levy R. PMID: 11823048.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    John's Networks
    Concepts (317)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (25)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California